Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
Abstract Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein sign...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-020-01662-5 |
id |
doaj-442dc4d633c04047b3e301b119b02ba9 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bo Jia Zhi Dong Di Wu Jun Zhao Meina Wu Tongtong An Yuyan Wang Minglei Zhuo Jianjie Li Yang Wang Jie Zhang Xinghui Zhao Sheng Li Junfeng Li Menglei Ma Chen Chen Xue Yang Jia Zhong Hanxiao Chen Jingjing Wang Yujia Chi Xiaoyu Zhai Song Cui Rong Zhang Qingwei Ma Jian Fang Ziping Wang |
spellingShingle |
Bo Jia Zhi Dong Di Wu Jun Zhao Meina Wu Tongtong An Yuyan Wang Minglei Zhuo Jianjie Li Yang Wang Jie Zhang Xinghui Zhao Sheng Li Junfeng Li Menglei Ma Chen Chen Xue Yang Jia Zhong Hanxiao Chen Jingjing Wang Yujia Chi Xiaoyu Zhai Song Cui Rong Zhang Qingwei Ma Jian Fang Ziping Wang Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients Cancer Cell International Lung adenocarcinoma Pemetrexed Prognosis Treatment VeriStrat |
author_facet |
Bo Jia Zhi Dong Di Wu Jun Zhao Meina Wu Tongtong An Yuyan Wang Minglei Zhuo Jianjie Li Yang Wang Jie Zhang Xinghui Zhao Sheng Li Junfeng Li Menglei Ma Chen Chen Xue Yang Jia Zhong Hanxiao Chen Jingjing Wang Yujia Chi Xiaoyu Zhai Song Cui Rong Zhang Qingwei Ma Jian Fang Ziping Wang |
author_sort |
Bo Jia |
title |
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients |
title_short |
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients |
title_full |
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients |
title_fullStr |
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients |
title_full_unstemmed |
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients |
title_sort |
prediction of the veristrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients |
publisher |
BMC |
series |
Cancer Cell International |
issn |
1475-2867 |
publishDate |
2020-12-01 |
description |
Abstract Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein signature (VeriStrat, VS) to analyze whether VS could identify the subset of patients who had poor efficacy on pemetrexed therapy. Methods This study retrospectively analysed 72 advanced lung adenocarcinoma patients who received first-line pemetrexed/platinum or combined with bevacizumab treatment. Results Plasma samples from these patients were analysed using VS and classified into the Good (VS-G) or Poor (VS-P) group. The relationship between efficacy and VS status was further investigated. Of the 72 patients included in this study, 35 (48.6%) were treated with pemetrexed plus platinum and 37 (51.4%) were treated with pemetrexed/platinum combined with bevacizumab. Among all patients, 60 (83.3%) and 12 (16.7%) patients were classified as VS-G and VS-P, respectively. VS-G patients had significantly better median progression-free survival (PFS) (Unreached vs. 4.2 months; P < 0.001) than VS-P patients. In addition, the partial response (PR) rate was higher in the VS-G group than that in the VS-P group (46.7% vs. 25.0%, P = 0.212). Subgroup analysis showed that PFS was also significantly longer in the VS-G group than that in the VS-P group regardless of whether patients received chemotherapy alone or chemotherapy plus bevacizumab. Conclusions Our study indicated that VS might be considered as a novel and valid method to predict the efficacy of pemetrexed-based therapy and identify a subset of advanced lung adenocarcinoma patients who had intrinsic resistance to pemetrexed based regimens. However, larger sample studies are still needed to further confirm this result. |
topic |
Lung adenocarcinoma Pemetrexed Prognosis Treatment VeriStrat |
url |
https://doi.org/10.1186/s12935-020-01662-5 |
work_keys_str_mv |
AT bojia predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT zhidong predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT diwu predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT junzhao predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT meinawu predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT tongtongan predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT yuyanwang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT mingleizhuo predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT jianjieli predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT yangwang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT jiezhang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT xinghuizhao predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT shengli predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT junfengli predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT mengleima predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT chenchen predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT xueyang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT jiazhong predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT hanxiaochen predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT jingjingwang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT yujiachi predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT xiaoyuzhai predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT songcui predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT rongzhang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT qingweima predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT jianfang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients AT zipingwang predictionoftheveristrattestinfirstlinetherapyofpemetrexedbasedregimensforadvancedlungadenocarcinomapatients |
_version_ |
1724385024032112640 |
spelling |
doaj-442dc4d633c04047b3e301b119b02ba92020-12-13T12:17:00ZengBMCCancer Cell International1475-28672020-12-012011710.1186/s12935-020-01662-5Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patientsBo Jia0Zhi Dong1Di Wu2Jun Zhao3Meina Wu4Tongtong An5Yuyan Wang6Minglei Zhuo7Jianjie Li8Yang Wang9Jie Zhang10Xinghui Zhao11Sheng Li12Junfeng Li13Menglei Ma14Chen Chen15Xue Yang16Jia Zhong17Hanxiao Chen18Jingjing Wang19Yujia Chi20Xiaoyu Zhai21Song Cui22Rong Zhang23Qingwei Ma24Jian Fang25Ziping Wang26Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of GI Oncology, Peking University Cancer Hospital & InstituteKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital & InstituteKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteCenter for Clinical Laboratory Medicine, Chinese PLA General Hospital, The First Medical Center)Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteBioyong Technologies IncBioyong Technologies IncBioyong Technologies IncKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital & InstituteKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & InstituteAbstract Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein signature (VeriStrat, VS) to analyze whether VS could identify the subset of patients who had poor efficacy on pemetrexed therapy. Methods This study retrospectively analysed 72 advanced lung adenocarcinoma patients who received first-line pemetrexed/platinum or combined with bevacizumab treatment. Results Plasma samples from these patients were analysed using VS and classified into the Good (VS-G) or Poor (VS-P) group. The relationship between efficacy and VS status was further investigated. Of the 72 patients included in this study, 35 (48.6%) were treated with pemetrexed plus platinum and 37 (51.4%) were treated with pemetrexed/platinum combined with bevacizumab. Among all patients, 60 (83.3%) and 12 (16.7%) patients were classified as VS-G and VS-P, respectively. VS-G patients had significantly better median progression-free survival (PFS) (Unreached vs. 4.2 months; P < 0.001) than VS-P patients. In addition, the partial response (PR) rate was higher in the VS-G group than that in the VS-P group (46.7% vs. 25.0%, P = 0.212). Subgroup analysis showed that PFS was also significantly longer in the VS-G group than that in the VS-P group regardless of whether patients received chemotherapy alone or chemotherapy plus bevacizumab. Conclusions Our study indicated that VS might be considered as a novel and valid method to predict the efficacy of pemetrexed-based therapy and identify a subset of advanced lung adenocarcinoma patients who had intrinsic resistance to pemetrexed based regimens. However, larger sample studies are still needed to further confirm this result.https://doi.org/10.1186/s12935-020-01662-5Lung adenocarcinomaPemetrexedPrognosisTreatmentVeriStrat |